Concepedia

Author

Hironori Ninomiya

Japanese Foundation For Cancer ResearchORCID

Also Known As

H Ninomiya, H. NINOMIYA, H. Ninomiya, HIRONORI NINOMIYA, Hideaki NINOMIYA, Hironori NINOMIYA, Hironori Ninomiya, Ninomiya H

163

Publications

4.6K

Citations

28

H-Index

61

Concepts

All Affiliations

Japanese Foundation For Cancer ResearchThe Cancer Institute HospitalTokyo Medical and Dental UniversityKitasato UniversityCancer Institute (WIA)
HN

About

Hironori Ninomiya is an author at Japanese Foundation For Cancer Research specializing in medicine, pathology, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

28

3.2K

2

Cell Biology

12

13

2.8K

3

Health Sciences

3

3

98

4

Public Health

2

2

44

5

Biology

1

1

28

Hironori Ninomiya

×

57

Publications

4.3K

Citations

28

H-Index

YearCitations

RET, ROS1 and ALK fusions in lung cancer

Kengo Takeuchi, Manabu Soda, Yuki Togashi,

Nature Medicine

2012

1.3K

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

Kentaro Inamura, Kengo Takeuchi, Yuki Togashi,

Journal of Thoracic Oncology

2008

464

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset

Kentaro Inamura, Kengo Takeuchi, Yuki Togashi,

Modern Pathology

2009

443

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani,

EBioMedicine

2015

139

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer

Rie Sakakibara, Kentaro Inamura, Yuichi Tambo,

Clinical Lung Cancer

2016

127

Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes

Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi,

Oncotarget

2017

108

Correlation between morphology and EGFR mutations in lung adenocarcinomas

Hironori Ninomiya, Miyako Hiramatsu, Kentaro Inamura,

Lung Cancer

2008

101

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status

Koji Fukuda, Shinji Takeuchi, Sachiko Arai,

Cancer Research

2019

94

Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis

Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi,

Lung Cancer

2016

89

Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?

Kentaro Inamura, Hironori Ninomiya, Yuichi Ishikawa,

PubMed

2010

78

Page 1